Evaluation of HER2 Gene Amplification using CISH in Patients with HER2 2+ (equivocal) Breast Carcinoma based on Immunohistochemistry in Imam Khomeini Cancer Institute from 2016 to 2018

Background: Human epidermal growth factor 2 (HER2) is known to be an important prognostic in breast cancer. Numerous studies have shown HER2+ cancers reduced overall survival and recovery time, as well the efficacy of anti-HER2 therapies along with chemotherapy improving disease outcomes. For this reason, it recommended that all patients cancer should evaluated for HER2 status. This study aimed assess gene amplification by CISH method evaluating status immunohistochemistry (IHC) 2+ (equivocal) results. Methods: retrospective cross-sectional examined based on Chromogenic situ hybridization (CISH) 280 carcinoma samples initial score IHC. The relationship between hormone receptors (estrogen progesterone) Ki67 level was also investigated. Results: In sixty (21.4%), amplified method. majority (215, 76.8%) were negative 5 (1.8%) indeterminate. No significant observed amplification, estrogen receptor (p=0.143), ki.67 protein (p=0.977). There a inverse progesterone positivity (p=0.007). Conclusion: These results demonstrate helpful equivocal positive (amplified) about 21.4% them.